Investor Presentation

7 ● ● ● History of "Pipeline in a Product" for Successful Drugs Targeting Inflammation ● 1,2 4 of top 5 top-selling US drugs (2016) with combined sales of $42 billion in 2017¹, Rituxan Rituximab $9B 2017 WW sales² FDA Approved For: Rheumatoid arthritis (RA) Non-Hodgkin's Lymphoma (NHL) Chronic Lymphocytic Leukemia (CLL) Granulomatosis With Polyangiitis (GPA) & Microscopic Polyangiitis (MPA) • Pemphigus Vulgaris (PV) Approved:1997 Roche MAS.. ● ● ● 2₂ Enbrel etanercept $8B 2017 WW sales² FDA Approved For: Rheumatoid arthritis (RA) Juvenile idiopathic arthritis (JIA) Psoriatic arthritis (PSA) Ankylosing spondylitis (AS) Psoriasis (Ps) Approved: 1998 AMGEN 1: IgeaHub (August 8, 2017) Top 20 Drugs in the World 2017; 2: statistica.com ● ● ● ● Remicade INFLIXIMAB $7B 2017 WW sales² FDA Approved For: Rheumatoid arthritis (RA) Psoriatic arthritis (PSA) Ankylosing spondylitis (AS) Crohn's disease (CD) Psoriasis (Ps) Ulcerative colitis (UC) Approved: 1999 Johnson & Johnson 200. e e e e @ ● Significant Market Opportunity ● HUMIRAⓇ adalimumab $18B 2017 WW sales² FDA Approved For: Rheumatoid arthritis (RA) Juvenile idiopathic arthritis (JIA) Psoriatic arthritis (PSA) Ankylosing spondylitis (AS) Crohn's disease (CD) Hidradenitis suppurativa (HS) Psoriasis (Ps) Ulcerative colitis (UC) Approved: 2002 abbvie

View entire presentation